Jacky Luiten

Valorization | 147 V References 1. Fracheboud J, de Koning HJ, Boer R, Groenewoud JH, Verbeek AL, Broeders MJ, et al. Nationwide breast cancer screening programme fully implemented in The Netherlands. Breast (Edinburgh, Scotland). 2001;10(1):6 ‐ 11. 2. den Heeten GJ, Broeders MJ. Nationwide breast cancer screening in the Neth erlands. Medica Mudi. 2009;53(1):4. 3. IKNL. Monitor bevolkingsonderzoek [cited 2020 Jan]. Available from: https://www.iknl.nl/ getmedia/15bd0ea1 ‐ eb30 ‐ 4647 ‐ 82b8 ‐ 12e11c3dbe9c/Monitor ‐ bevolkingson derzoek ‐ borstkanker ‐ 2017 ‐ 2018_IKNL.pdf. 4. Jacklyn G, McGeechan K, Irwig L, Houssami N, Morrell S, Bell K, et al. Trends in stage ‐ specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography. Breast Cancer Res Treat. 2017;166(3):843 ‐ 854. 5. Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hubner J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program2019 Nov 1; Int J Cancer. Epub ahead of print. 6. de Munck L, Fracheboud J, de Bock GH, den Heeten GJ, Siesling S, Broeders MJM. Is the incidence of advanced ‐ stage breast cancer affected by whether women attend a steady ‐ state screening program? Int J Cancer. 2018;143(4):842 ‐ 850. 7. Thomas ET, Del Mar C, Glasziou P, Wright G, Barratt A, Bell KJL. Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta ‐ analysis. BMC Cancer. 2017;17(1):808. 8. Jorgensen KJ, Gotzsche PC, Kalager M, Zahl PH. Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Ann Intern Med. 2017;166(5):313 ‐ 323. 9. de Gelder R. Predicting the Benefits and Harms of Breast Cancer Screening: Current debates and future directions [Ph.D. thesis]: Erasmus MC: University Medical Center Rotterdam; 2012. 10. Seigneurin A, Labarere J, Francois O, Exbrayat C, Dupouy M, Filippi M, et al. Overdiagnosis and overtreatment associated with breast cancer mammography screening: A simulation study with calibration to population ‐ based data. Breast (Edinburgh, Scotland). 2016;28:60 ‐ 66. 11. Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, et al. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005;7(6):258 ‐ 265. 12. de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population ‐ based mammography screening. Epidemiol Rev. 2011;33:111 ‐ 121. 13. Honig EL, Mullen LA, Amir T, Alvin MD, Jones MK, Ambinder EB, et al. Factors Impacting False Positive Recall in Screening Mammography. Acad Radiol. 2019;26(11):1505 ‐ 1512. 14. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long ‐ term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12(1):21 ‐ 29. 15. Ellis IO. Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. Mod Pathol. 2010;23 Suppl 2:S1 ‐ 7. 16. Sajid MS, Parampalli U, Haider Z, Bonomi R. Comparison of radioguided occult lesion localization (ROLL) and wire localization for non ‐ palpable breast cancers: a meta ‐ analysis. J Surg Oncol. 2012;105(8):852 ‐ 858. 17. Lovrics PJ, Goldsmith CH, Hodgson N, McCready D, Gohla G, Boylan C, et al. A multicentered, randomized, controlled trial comparing radioguided seed localization to standard wire localization for nonpalpable, invasive and in situ breast carcinomas. Ann Surg Oncol. 2011;18(12):3407 ‐ 3414. 18. Bloomquist EV, Ajkay N, Patil S, Collett AE, Frazier TG, Barrio AV. A Randomized Prospective Comparison of Patient ‐ Assessed Satisfaction and Clinical Outcomes with Radioactive Seed Localization versus Wire Localization. Breast J. 2016;22(2):151 ‐ 157.